Cell line name |
MBA72R |
Accession |
CVCL_A2FZ |
Resource Identification Initiative |
To cite this cell line use: MBA72R (RRID:CVCL_A2FZ) |
Comments |
Selected for resistance to: ChEBI; CHEBI_91367; Barasertib-HQPA (AZD1152-HQPA). Miscellaneous: Age/sex of donor and metastatic site from personal communication of Guida, Gabriella. Derived from site: Metastatic; Right temple; UBERON=UBERON_8480027. |
Sequence variations |
- Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Val92Met (c.274G>A); ClinVar=VCV000014308; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (from parent cell line).
|
Disease |
Melanoma (NCIt: C3224) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_A2FY (MBA72) |
Sex of cell |
Male |
Age at sampling |
82Y |
Category |
Cancer cell line |
Publications | DOI=10.1186/1479-5876-12-S1-P7 Azzariti A., Porcelli L., Quatrale A.E., Sidella L., Iacobazzi R.M., Guida G., Maida I., Cocco T., Ferretta A., Strippoli S., Guida S., Tommasi S., Paradiso A., Guida M. Barasertib: a novel approach for the treatment of metastatic melanoma. J. Transl. Med. 12 Suppl. 1:P7-P7(2014) PubMed=25623468; DOI=10.1186/s12967-015-0385-4; PMCID=PMC4314759 Porcelli L., Guida G., Quatrale A.E., Cocco T., Sidella L., Maida I., Iacobazzi R.M., Ferretta A., Stolfa D.A., Strippoli S., Guida S., Tommasi S., Guida M., Azzariti A. Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. J. Transl. Med. 13:26.1-26.13(2015) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_A2FZ
|
Encyclopedic resources |
Wikidata; Q105510040
|
Entry history |
Entry creation | 12-Jan-2021 |
Last entry update | 19-Dec-2024 |
Version number | 7 |
---|